[F:1][C:2]1[C:3]2[CH:4]=[C:5]3[C:14]4[N:15]=[C:16]([C:19]5[C:20]([N:38]([CH3:43])[S:39]([CH3:42])(=[O:41])=[O:40])=[CH:21][C:22]6[O:26][C:25]([C:27]7[CH:32]=[CH:31][C:30]([F:33])=[CH:29][CH:28]=7)=[C:24]([C:34]([OH:36])=O)[C:23]=6[CH:37]=5)[CH:17]=[CH:18][C:13]=4[O:12][CH2:11][N:6]3[C:7]=2[CH:8]=[CH:9][CH:10]=1.C1C=CC2N(O)N=[N:50]C=2C=1.CCN=C=NCCCN(C)C.[NH4+].[Cl-]>CN(C=O)C.O.CCN(CC)CC>[F:1][C:2]1[C:3]2[CH:4]=[C:5]3[C:14]4[N:15]=[C:16]([C:19]5[C:20]([N:38]([CH3:43])[S:39]([CH3:42])(=[O:41])=[O:40])=[CH:21][C:22]6[O:26][C:25]([C:27]7[CH:28]=[CH:29][C:30]([F:33])=[CH:31][CH:32]=7)=[C:24]([C:34]([NH2:50])=[O:36])[C:23]=6[CH:37]=5)[CH:17]=[CH:18][C:13]=4[O:12][CH2:11][N:6]3[C:7]=2[CH:8]=[CH:9][CH:10]=15-(11-fluoro-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(4-fluorophenyl)-6-(N-methylmethylsulfonamido)benzofuran-3-carboxylic acid (200 mg, 0.33 mmol), HOBT (50 mg, 0.37 mmol) and EDCI (140 mg, 0.73 mmol) were dissolved in dry DMF (5 mL). The resulting solution was stirred for 2 hours. And then NH4Cl (100 mg, 1.87 mmol) and Et3N (0.5 mL) were added to the mixture. The mixture was stirred at room temperature overnight. Then H2O was added, and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified using column chromatography (dichloromethane:MeOH=40:1) to provide 5-(11-fluoro-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(4-fluorophenyl)-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (180 mg, yield: 90%). 1H-NMR (CDCl3, 400 MHz) δ 8.14 (s, 1H), 7.98˜8.03 (m, 2H), 7.69 (s, 1H), 7.48˜7.54 (m, 2H), 7.19˜7.24 (m, 4H), 7.12 (d, J=8.4 Hz, 1H), 6.83˜6.88 (m, 1H), 6.01 (s, 2H), 5.70˜5.86 (m, 2H), 3.39 (s, 3H), 2.74 (s, 3H). MS (M+H)+: 601.